Clinical trials: Ticagrelor
Antiplatelet Drug, Acute Coronary Syndrome
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel coated to the balloon.
- Conditions
- Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon
- Trial name
- CAGEFREEII (NCT04971356)
- Testing
- Aspirin 100mg for 1-month (immediately after PCI), Ticagrelor 90mg for 6-month (immediately after PCI), Aspirin 100mg for 6-month (6-month post PCI)
- Where
- China
- Volunteers
- 1,948 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndrome
Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)
1. Objective : To test the safety of 6 month-duration of dual antiplatelet therapy (DAPT) compared to conventional 12-month-or-longer duration after second-generation drug-eluting stent (DES) implantation in patients with acute…
- Trial name
- SMART-DATE (NCT01701453)
- Testing
- P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
- Where
- South Korea
- Volunteers
- 2,712 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study
Endothelial dysfunction is an important predictor - and a determinant - of adverse clinical outcome. Endothelial function is impaired by coronary artery stenting, a stud from our group has shown that it can be improved by…
- Trial name
- EST (NCT01700322)
- Testing
- Coronary stenting, Ticagrelor, Clopidogrel
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Johannes Gutenberg University Mainz
Dyspnea
Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity
Research project objectives: Most common complication of P2Y12 inhibitors treatment, particularly with ticagrelor, is dyspnea reported in 0 to 9.3% and in 10 to 38.6% of patients taking clopidogrel and ticagrelor respectively.
- Trial name
- NCT05080478
- Testing
- Clopidogrel, Ticagrelor
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Wroclaw Medical University
Hepatic Artery Thrombosis, Liver Transplant; Complications
Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)
Hepatic artery thrombosis (HAT) represents a major cause of graft loss and mortality after Pediatric liver transplantation. Ticagrelor (a new reversible inhibitor of P2Y12 receptor with faster onset of action and greater platelet…
- Conditions
- Hepatic Artery Thrombosis, Liver Transplant; Complications, Pediatric Disease
- Trial name
- Tip-HAT (NCT04946929)
- Testing
- Ticagrelor Oral Tablet [Brilinta], Low molecular weight heparin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Percutaneous Coronary Intervention
Chewed Versus Integral Pill of Ticagrelor
Hypothesis The primary question the investigators propose to answer is whether all patients undergoing percutaneous coronary intervention (PCI) with stent deployment who receive chewed ticagrelor will demonstrate more rapid drug…
- Trial name
- NCT03708588
- Testing
- Ticagrelor
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Wake Forest University Health Sciences
Acute ST-elevation Myocardial Infarction
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction
Adequate platelet inhibition with dual antiplatelet therapy is a key therapeutic goal after primary percutaneous coronary intervention (PPCI), aimed at protecting against stent thrombosis and increased mortality.
- Trial name
- PLATFORM (NCT01739556)
- Testing
- Antiplatelet Regimen Modification (aspirin or ticagrelor)
- Where
- Serbia
- Volunteers
- 242 people
- Sponsor
- Clinical Centre of Serbia
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Myocardial Infarction, STEMI
Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with stent implantation to prevent atherothrombotic…
- Trial name
- NCT01761786
- Testing
- CYP2C19 genotyping
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 2,700 people
- Sponsor
- Vera HM Deneer
Coronary Artery Disease
STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation
Most previous trials support the absolute increase in bleeding risk with perioperative administration of antiplatelet. Furthermore, recent studies demonstrated that perioperative major bleeding may be related to increase…
- Trial name
- NCT03184805
- Testing
- Continuing aspirin, Stopping aspirin
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
- Trial name
- NCT03447379
- Testing
- P2Y12 antagonist monotherapy, Aspirin plus P2Y12 antagonist
- Where
- South Korea
- Volunteers
- 1,452 people
- Sponsor
- Gangnam Severance Hospital
Ischemic Stroke, TIA
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers.
- Trial name
- READAPT (NCT05476081)
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 127 sites in Italy
- Volunteers
- 2,239 people
- Sponsor
- University of L'Aquila
Non ST Segment Elevation Acute Coronary Syndrome
Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS
The aim of the study is to learn more about the pathophysiology of acute coronary syndrome (ACS) and to evaluate the mechanisms responsible of the action and benefits of ticagrelor.
- Trial name
- TIGER-M (NCT02071966)
- Testing
- Ticagrelor, Clopidogrel
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Catholic University of the Sacred Heart
Anticoagulation, Coronary Endarterectomy
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients.
- Trial name
- NCT05782270
- Testing
- Warfarin, DAPT, CE+CABG
- Where
- China
- Volunteers
- 202 people
- Sponsor
- China National Center for Cardiovascular Diseases
ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation…
- Conditions
- ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions
- Trial name
- IMPRESSION (NCT02217878)
- Testing
- Morphine, Ticagrelor
- Where
- Poland
- Volunteers
- 74 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Coronary Artery Disease
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10).
- Trial name
- NCT06228456
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Sickle Cell Disease
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
- Trial name
- Hestia2 (NCT02482298)
- Testing
- Ticagrelor
- Where
- 20 sites in United States, Egypt and 6 more
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome, Myocardial Ischemia
Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management
The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.
- Conditions
- Acute Coronary Syndrome, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases
- Trial name
- TICA KOREA (NCT02094963)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 10 sites in South Korea
- Volunteers
- 800 people
- Sponsor
- Seung-Jung Park